Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
G.B. Migliori, S. Ahuja, D. Ashkin, M. Avendano, R. Banerjee, M. Bauer, J. Bayona, M. Becerra, A. Benedetti, M. Burgos, R. Centis, E.D. Chan, C.Y. Chiang, H. Cox, L. D‘Ambrosio, K. DeRiemer, N.H. Dung, D. Enarson, K. Flanagan, J. Flood, M.L. Garcia-Garcia, N. Gandhi, R. Granich, M.G. Hollm-Delgado, T.H. Holtz, M. Iseman, L. Jarlsberg, S. Keshavjee, H.R. Kim, W.J. Koh, J. Lancaster, C. Lange, W.C.M. de Lange, V. Leimane, C.C. Leung, J. Li, S. Mishustin, C. Mitnick, M. Narita, P. O‘Riordan, M. Pai, D. Palmero, S.K. Park, G. Pasvol, J. Pena, C. Pérez-Guzmán, M. Quelapio, A. Ponce-de-Leon, V. Riekstina, J. Robert, S. Royce, H.S. Schaaf, K.J. Seung, L. Shah, T.S. Shim, S.S. Shin, Y. Shiraishi, J. Sifuentes-Osornio, G. Sotgiu, M.J. Strand, P. Tabarsi, T.E. Tupasi, R. van Altena, M. Van der Walt, T.S. Van der Werf, M.H. Vargas, P. Viiklepp, J. Westenhouse, W.W. Yew, J.J. Yim, D. Menzies (Tradate, Italy; Long Island City, Lantana, Rochester, Hanover, Boston, Albuquerque, Denver, Davis, Richmond, Bronx, Atlanta, San Francisco, New York, Seattle, United States Of America; Toronto, Montreal, Canada; Paris, France; Taipei City, Taiwan; Cape Town, Pretoria, Tygerberg, South Africa; Ho Chi Minh City, Viet Nam; Tasmania, Australia; Cuernavaca, Aguascalientes, Mexico City, Mexico; Geneva, Switzerland; Seoul, Masan City, Republic Of Korea; Borstel, Germany; Groningen, Netherlands; Upeslejas, Latvia; Hong Kong, Hong Kong; Tomsk, Russian Federation; London, United Kingdom; Buenos Aires, Argentina; Madrid, Spain; Makati, Philippines; , ; Tokyo, Japan; Tehran, Islamic Republic Of Iran; Tallinn, Estonia). Outcomes for multidrug-resistant tuberculosis patients with and without resistance to fluoroquinolones and second-line injectable drugs: A meta-analysis of individual patient data. Eur Respir J 2012; 40: Suppl. 56, 4286

Member's Comments

No comment yet.

Related content which might interest you: Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes Source: Eur Respir J 2013; 42: 156-168 Year: 2013 Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China Source: Eur Respir J, 57 (3) 2003463; 10.1183/13993003.03463-2020 Year: 2021 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008 Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 A study on the clinical efficacy of a combination regimen with azithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 722s Year: 2004 Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002 Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB Source: Eur Respir J 2009; 33: 581-585 Year: 2009 Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Efficacy of empiric chemotherapy regimen in patients with multidrug resistant (MDR) tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 656s Year: 2004 Treatment of resistant tuberculosis in patients having isolates resistant to multiple antituberculosis drugs Source: Annual Congress 2010 - Prognosis of tuberculosis Year: 2010 Cost-effectiveness analysis of regimens chemotherapy in patients with multidrug resistant tuberculosis (MDR TB) compared with standard regimen in patients with susceptible MBT Source: Eur Respir J 2003; 22: Suppl. 45, 526s Year: 2003 Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis Source: Eur Respir J 2013; 42: 169-179 Year: 2013 Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 Adverse effects of second-line drugs during the treatment of multidrug resistant tuberculosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 650s Year: 2005 The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 The efficacy of treatment of patients with drug resistant tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 661s Year: 2007 Resistance of sputum nonspecific microflora in MDR TB patients treated with second-line anti-TB drugs Source: Eur Respir J 2002; 20: Suppl. 38, 614s Year: 2002 A UK cost comparison of amikacin therapy with bedaquiline, for drug resistant tuberculosis Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis Source: Eur Respir J 2017; 49(1): 1600993; DOI: 10.1183/13993003.00993-2016 Year: 2017 Resistance to second-line antituberculous drugs of Mtb strains in TB institute clinic Source: Eur Respir J 2007; 30: Suppl. 51, 442s Year: 2007